122 related articles for article (PubMed ID: 21262383)
1. Antiangiogenic therapy using nanotechnological-based delivery system.
Kanwar JR; Mahidhara G; Kanwar RK
Drug Discov Today; 2011 Mar; 16(5-6):188-202. PubMed ID: 21262383
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
3. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle and targeted systems for cancer therapy.
Brannon-Peppas L; Blanchette JO
Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
[TBL] [Abstract][Full Text] [Related]
5. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
Talekar M; Kendall J; Denny W; Garg S
Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
[TBL] [Abstract][Full Text] [Related]
6. Metronomic chemotherapy: Back to the future!
André N; Padovani L; Verschuur A
Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
[TBL] [Abstract][Full Text] [Related]
7. Overview of targeted therapies in oncology.
Kalyn R
J Oncol Pharm Pract; 2007 Dec; 13(4):199-205. PubMed ID: 18045779
[TBL] [Abstract][Full Text] [Related]
8. Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents.
Konson A; Pradeep S; Seger R
Cancer Res; 2010 Aug; 70(15):6247-57. PubMed ID: 20610633
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic anticancer strategy based on nanoparticulate systems.
Yoncheva K; Momekov G
Expert Opin Drug Deliv; 2011 Aug; 8(8):1041-56. PubMed ID: 21585229
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology for antiangiogenic cancer therapy.
Kobayashi H; Lin PC
Nanomedicine (Lond); 2006 Jun; 1(1):17-22. PubMed ID: 17716205
[TBL] [Abstract][Full Text] [Related]
11. Current strategies and future directions of antiangiogenic tumor therapy.
Zhang ZL; Wang JH; Liu XY
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
[TBL] [Abstract][Full Text] [Related]
12. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity.
Radhakrishnan SK; Gartel AL
Cancer Res; 2006 Mar; 66(6):3264-70. PubMed ID: 16540679
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
Schultze A; Fiedler W
Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
16. The development and testing of aptamers for cancer.
Barbas AS; White RR
Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
[TBL] [Abstract][Full Text] [Related]
17. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
18. Cationic nanoparticles for cancer therapy.
Bilensoy E
Expert Opin Drug Deliv; 2010 Jul; 7(7):795-809. PubMed ID: 20446858
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
Mendoza FJ; Espino PS; Cann KL; Bristow N; McCrea K; Los M
Arch Immunol Ther Exp (Warsz); 2005; 53(1):47-60. PubMed ID: 15761376
[TBL] [Abstract][Full Text] [Related]
20. Prospective strategies to enforce selectively cell death in cancer cells.
Blagosklonny MV
Oncogene; 2004 Apr; 23(16):2967-75. PubMed ID: 15077157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
